Login to Your Account



Other News To Note


Monday, July 29, 2013
• Furiex Pharmaceuticals Inc., of Morrisville, N.C., confirmed that Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, got a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Vipidia (alogliptin), and fixed-dose combinations Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone) for the treatment of Type II diabetes patients who are uncontrolled on existing therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription